银丹心脑通联合钙通道阻断剂治疗高血压患者的疗效及安全性分析  

Efficacy and Safety of Yindanxinnaotong Combined with Calcium Channel Blocker in the Treatment of Patients with Hypertension

作　　者：刘楚言 Liu Chuyan(Department of General Medicine,Dancheng People's Hospital,Zhoukou 477150)

机构地区：[1]郸城县人民医院全科医学科,周口477150

出　　处：《数理医药学杂志》2021年第3期436-437,共2页Journal of Mathematical Medicine

摘　　要：目的:分析银丹心脑通联合钙通道阻断剂治疗高血压患者的疗效和安全性。方法:选取2017年12月~2019年4月某院收治的高血压患者96例,按治疗方案不同分为研究组与对照组各48例,对照组予以钙通道阻断剂,研究组在对照组基础上予以银丹心脑通,对比两组疗效和不良反应发生率。结果:研究组总有效率91.67%(44/48)较对照组72.92%(35/48)高(P<0.05);研究组不良反应发生率2.08%(1/48)与对照组2.08%(1/48)相比无显著差异(P>0.05)。结论:在钙通道阻断剂治疗高血压患者基础上加用银丹心脑通效果显著,且未增加不良反应发生率,值得临床推广应用。Objective:To analyze the efficacy and safety of Yindanxinnaotong combined with calcium channel blocker in the treatment of hypertensive patients.Methods:A total of 96 patients with hypertension in a hospital from December 2017 to April 2019 were selected and divided into the study group(n=48)and the control group(n=48).The control group was given calcium channel block,and the study group was given Yindanxintong on the basis of the control group.The efficacy and incidence of adverse reactions between the two groups were compared.Results:The total effective rate of the study group was 91.67%(44/48),which was higher than that of the control group(72.92%(35/48)).The incidence of adverse reactions was 2.08%(1/48)in the study group and 2.08%in the control group(1/48),There was no significant difference(P>0.05).Conclusion:The effect of adding Yindanxinnao on the basis of calcium channel blocker in the treatment of hypertensive patients is significant,and the incidence of adverse reactions is not increased,which is worthy of clinical application.

关 键 词：银丹心脑通 钙通道阻断剂 高血压 

分 类 号：R544.1[医药卫生—心血管疾病]